Search Site
  • 0
    My Cart

    Click Here to Find How Many Items You Have Added:)

    image loader

    Adding item(s) to cart......

Home >> Signaling Pathways >> DNA Damage/DNA Repair >> CDK

CDK

<div class="colum_1 clearer"><p>CDKs (Cyclin-dependent kinases) are serine-threonine kinases first discovered for their role in regulating the cell cycle. They are also involved in regulating transcription, mRNA processing, and the differentiation of nerve cells. CDKs are relatively small proteins, with molecular weights ranging from 34 to 40 kDa, and contain little more than the kinase domain. In fact, yeast cells can proliferate normally when their CDK gene has been replaced with the homologous human gene. By definition, a CDK binds a regulatory protein called a cyclin. Without cyclin, CDK has little kinase activity; only the cyclin-CDK complex is an active kinase.</p><p>There are around 20 Cyclin-dependent kinases (CDK1-20) known till date. CDK1, 4 and 5 are involved in cell cycle, and CDK 7, 8, 9 and 11 are associated with transcription.</p><p>CDK levels remain relatively constant throughout the cell cycle and most regulation is post-translational. Most knowledge of CDK structure and function is based on CDKs of <i>S. pombe</i> (Cdc2), <i>S. cerevisia</i> (CDC28), and vertebrates (CDC2 and CDK2). The four major mechanisms of CDK regulation are cyclin binding, CAK phosphorylation, regulatory inhibitory phosphorylation, and binding of CDK inhibitory subunits (CKIs).</p></div>

Targets for  CDK

Products for  CDK

  1. Cat.No. Product Name Information
  2. GC36062 FMF-04-159-2 FMF-04-159-2 is a covalent CDK14 inhibitor. FMF-04-159-2 inhibits CDK14 and CDK2 with IC50s of 39.6 nM and 256 nM in NanoBRET assay, respectively. FMF-04-159-2 Chemical Structure
  3. GC50719 FMF-04-159-R FMF-04-159-R Chemical Structure
  4. GC33049 FN-1501 FN-1501 is a potent inhibitor of FLT3 and CDK, with IC50s of 2.47, 0.85, 1.96, and 0.28 nM for CDK2/cyclin A, CDK4/cyclin D1, CDK6/cyclin D1 and FLT3, respectively. FN-1501 has anticancer activity. FN-1501 Chemical Structure
  5. GN10696 Garcinone C Garcinone C Chemical Structure
  6. GC64926 GFB-12811 GFB-12811 is a high selective and orally active CDK5 inhibitor with an IC50 of 2.3 nM. GFB-12811 Chemical Structure
  7. GC14987 GSK-3 Inhibitor IX (BIO) GSK-3 Inhibitor IX (BIO) (6-Bromoindirubin-3'-oxime; BIO) is a potent, selective, reversible and ATP-competitive inhibitor of GSK-3α/β and CDK1-cyclinB complex with IC50s of 5 nM/320 nM/80 nM for (GSK-3α/β)/CDK1/CDK5, respectively. GSK-3 Inhibitor IX (BIO) Chemical Structure
  8. GC62423 GSK-3/CDK5/CDK2-IN-1 GSK-3/CDK5/CDK2-IN-1, an imidazole derivative, is an inhibitor of cdk5, cdk2, and GSK-3 extracted from patent WO2002010141A1, example 9a. GSK-3/CDK5/CDK2-IN-1 Chemical Structure
  9. GC63854 HQ461 HQ461 is a molecular glue that promotes CDK12-DDB1 interaction to trigger cyclin K degradation. HQ461-mediated degradation of cyclin K impairs CDK12 function, resulting in decreased CDK12 substrate phosphorylation, downregulation of DNA damage response genes, and cell death. HQ461 Chemical Structure
  10. GC62572 hSMG-1 inhibitor 11e hSMG-1 inhibitor 11e is a potent and selective hSMG-1 kinase inhibitor with an IC50 of 900-fold selectivity over mTOR (IC50 of 45 nM), PI3Kα/γ (IC50s of 61 nM and 92 nM) and CDK1/CDK2 (IC50s of 32 μM and 7.1 μM). hSMG-1 inhibitor 11e Chemical Structure
  11. GC61925 hSMG-1 inhibitor 11j hSMG-1 inhibitor 11j, a pyrimidine derivative, is a potent and selective inhibitor of hSMG-1, with an IC50 of 0.11 nM. hSMG-1 inhibitor 11j exhibits >455-fold selectivity for hSMG-1 over mTOR (IC50=50 nM), PI3Kα/γ (IC50=92/60 nM) and CDK1/CDK2 (IC50=32/7.1 μM). hSMG-1 inhibitor 11j can be used for the research of cancer. hSMG-1 inhibitor 11j Chemical Structure
  12. GC36312 Indirubin-3'-monoxime-5-sulphonic acid Indirubin-3'-monoxime-5-sulphonic acid is a potent and selective inhibitor of CDK1, CDK5, and GSK-3β with IC50s of 5 nM, 7 nM, and 80 nM, respectively. Indirubin-3'-monoxime-5-sulphonic acid Chemical Structure
  13. GC36313 Indirubin-5-sulfonate Indirubin-5-sulfonate is a cyclin-dependent kinase (CDK) inhibitor, with IC50 values of 55 nM, 35 nM, 150 nM, 300 nM and 65 nM for CDK1/cyclin B, CDK2/cyclin A, CDK2/cyclin E, CDK4/cyclin D1, and CDK5/p35, respectively. Indirubin-5-sulfonate also shows inhibitory activity against GSK-3β. Indirubin-5-sulfonate Chemical Structure
  14. GC63023 Ipivivint Ipivivint (compound 38) is a potent CDC-like kinase (CLK) inhibitor with EC50s of 1 nM, 7 nM for CLK2 and CLK3, respectively. Ipivivint inhibits Wnt pathway (EC50=13 nM). Ipivivint Chemical Structure
  15. GC63460 IV-361 IV-361 is an orally active and selective CDK7 inhibitor (Ki≤50 nM). IV-361 has anti-cancer activity (US20190256531A1). IV-361 Chemical Structure
  16. GC65471 JH-XI-10-02 JH-XI-10-02 is a PROTAC connected by ligands for Cereblon and CDK. JH-XI-10-02 is a highly potent and selective PROTAC CDK8 degrader, with an IC50 of 159 nM. JH-XI-10-02 causes proteasomal degradation, does not affect CDK8 mRNA levels. JH-XI-10-02 shows no effect on CDK19. JH-XI-10-02 Chemical Structure
  17. GC65577 JH-XVI-178 JH-XVI-178 is a highly potent and selective inhibitor of CDK8/19 that displays low clearance and moderate oral pharmacokinetic properties. JH-XVI-178 Chemical Structure
  18. GC12612 JNJ-7706621 A dual inhibitor of CDKs and Aurora kinases JNJ-7706621 Chemical Structure
  19. GC34204 JSH-150 JSH-150 is a highly selective and potent CDK9 inhibitor with an IC50 of 1 nM. JSH-150 Chemical Structure
  20. GC14230 K03861 K03861 (K03861) is a type II CDK2 inhibitor with Kd of 8.2 nM. K03861 (K03861) inhibits CDK2 activity by competing with binding of activating cyclins. K03861 Chemical Structure
  21. GC62392 KB-0742 dihydrochloride KB-0742 dihydrochloride is a potent, selective and orally active CDK9 inhibitor with an IC50 of 6 nM for CDK9/cyclin T1. KB-0742 dihydrochloride is selective for CDK9/cyclin T1 with >50-fold selectivity over other CDK kinases. KB-0742 dihydrochloride has potent anti-tumor activity. KB-0742 dihydrochloride Chemical Structure
  22. GC14182 Kenpaullone CDK1/cyclin B and GSK-3β inhibitor Kenpaullone Chemical Structure
  23. GC11774 KH CB19 inhibitor of CLK1 and CLK4, potent and selective KH CB19 Chemical Structure
  24. GC63943 KH-CB20 KH-CB20, an E/Z mixture, is a potent and selective inhibitor of CLK1 and the closely related isoform CLK4, with an IC50 of 16.5 nM for CLK1. KH-CB20 Chemical Structure
  25. GC50532 KuWal151 Potent and selective CLK inhibitor KuWal151 Chemical Structure
  26. GC17067 LDC000067 CDK9 inhibitor, novel and highly specific LDC000067 Chemical Structure
  27. GC19219 LDC4297 LDC4297 is a potent and selective CDK7 inhibitor with an IC50 of 0.13 nM. LDC4297 Chemical Structure
  28. GC66446 LDC4297 hydrochloride LDC4297 hydrochloride is a selective inhibitor of CDK7 with an IC50 value of 0.13 nM. LDC4297 hydrochloride inhibits human cytomegalovirus (HCMV) replication with an EC50 value of 24.5 nM. LDC4297 hydrochloride shows broad antiviral activities to Herpesviridae, Adenoviridae, Poxviridae, Retroviridae and Orthomyxoviridae with EC50 values of 0.02-1.21 μM. LDC4297 hydrochloride can be used for the research of infection. LDC4297 hydrochloride Chemical Structure
  29. GC10842 LEE011 LEE011 (LEE01) is a highly specific CDK4/6 inhibitor with IC50 values of 10 nM and 39 nM, respectively, and is over 1,000-fold less potent against the cyclin B/CDK1 complex. LEE011 Chemical Structure
  30. GC15922 LEE011 hydrochloride LEE011 hydrochloride (LEE011 hydrochloride) is a highly specific CDK4/6 inhibitor with IC50 values of 10 nM and 39 nM, respectively, and is over 1,000-fold less potent against the cyclin B/CDK1 complex. LEE011 hydrochloride Chemical Structure
  31. GC15377 LEE011 succinate LEE011 succinate (LEE011 succinate) is a highly specific CDK4/6 inhibitor with IC50 values of 10 nM and 39 nM, respectively, and is over 1,000-fold less potent against the cyclin B/CDK1 complex. LEE011 succinate Chemical Structure
  32. GC34163 Lerociclib (G1T38) Lerociclib (G1T38) (G1T38) is a potent and selective inhibitor of CDK4/6, with IC50s of 1 nM, 2 nM for CDK4/CyclinD1 and CDK6/CyclinD3, respectively. Lerociclib (G1T38) Chemical Structure
  33. GC34100 Lerociclib dihydrochloride (G1T38 dihydrochloride) Lerociclib dihydrochloride (G1T38 dihydrochloride) (G1T38 dihydrochloride) is a potent and selective inhibitor of CDK4/CDK6, with IC50s of 1 nM and 2 nM for CDK4/CyclinD1 and CDK6/CyclinD3, respectively. Lerociclib dihydrochloride (G1T38 dihydrochloride) Chemical Structure
  34. GC34650 Longdaysin

    Longdaysin is a inhibitor of the Wnt/β-catenin signaling pathway, which exerts antitumor effect through blocking CK1δ/ε-dependent Wnt signaling. Longdaysin inhibits CK1α, CK1δ, CDK7, and ERK2 with IC50s of? 5.6 ?M, 8.8 ?M, 29 ?M, and 52 ?M, respectively.

     Longdaysin Chemical Structure
  35. GC61008 LSN3106729 hydrochloride LSN3106729 hydrochloride Chemical Structure
  36. GC16822 LY2835219 LY2835219 (LY2835219 methanesulfonate) is a selective CDK4/6 inhibitor with IC50s of 2 nM and 10 nM for CDK4 and CDK6, respectively. LY2835219 Chemical Structure
  37. GC11823 LY2835219 free base A dual inhibitor of Cdk4 and Cdk6 LY2835219 free base Chemical Structure
  38. GC11971 LY2857785 CDK9 inhibitor LY2857785 Chemical Structure
  39. GC25593 LY3143921 hydrate LY3143921 hydrate is an orally administered ATP-competitive CDC7 inhibitor. LY3143921 hydrate Chemical Structure
  40. GC19233 LY3177833 LY3177833 is an CDC7 and pMCM2 inhibitor extracted from patent US 20140275131and patent WO 2014143601 A1 compound example 4; has IC50 values of 3.3 nM and 290 nM, respectively. LY3177833 Chemical Structure
  41. GC25594 LY3405105 LY3405105 is an orally active CDK7 inhibitor with an IC50 of 92.8 nM. LY3405105 shows potential antineoplastic activity. LY3405105 Chemical Structure
  42. GC32970 MBQ-167 MBQ-167 is a dual Rac/Cdc42 inhibitor, with IC50s of 103 nM for Rac 1/2/3 and 78 nM for Cdc42 in MDA-MB-231 cells, respectively. MBQ-167 Chemical Structure
  43. GC50239 ML 315 hydrochloride Inhibitor of Clk and DYRK kinases ML 315 hydrochloride Chemical Structure
  44. GC14162 ML167 Clk4 inhibitor,highly selective ML167 Chemical Structure
  45. GC32746 MSC2530818 A Cdk8 inhibitor MSC2530818 Chemical Structure
  46. GC64393 NCT02 NCT02 is a cyclin K degrader. NCT02 induces ubiquitination of cyclin K (CCNK) and proteasomal degradation of CCNK and its complex partner CDK12. NCT02 has the potential for the research of metastatic colorectal cancer (CRC). NCT02 Chemical Structure
  47. GC36732 NG 52 NG 52 is a potent, cell-permeable, selective, ATP-compatible and orally active Cdc28p and Pho85p kinase inhibitor with IC50s of 7 μM and 2 μM, respectively. NG 52 also inhibits the activity of phosphoglycerate kinase 1 (PGK1) with an IC50 of 2.5 μM. NG 52 is inactive against yeast kinases Kin28p, Srb10, and Cak1p. NG 52 Chemical Structure
  48. GC63874 NSC 107512 NSC 107512 is a potent inhibitor of cyclin-dependent kinase 9 (CDK9). NSC 107512 is a class of sangivamycin-like molecules (SLM). NSC 107512 inhibits growth and induces apoptosis of multiple myeloma tumors. NSC 107512 Chemical Structure
  49. GC19267 NU2058 NU2058 is a guanine-based CDK inhibitor with IC50 of 17 uM and 26 uM for CDK2 and CDK1. NU2058 Chemical Structure
  50. GC34692 NU6140 A Cdk2 inhibitor NU6140 Chemical Structure
  51. GC32829 NU6300 NU6300 is a covalent, irreversible and ATP-competitive CDK2 inhibitor with an IC50 value of 0.16 μM. NU6300 can be used for the research of eukaryotic cell cycle- and transcription-related. NU6300 Chemical Structure
  52. GC34056 NVP-2 NVP-2 is a potent and selective ATP-competitive cyclin dependent kinase 9 (CDK9) probe, inhibits CDK9/CycT activity with an IC50 of 0.514 nM. NVP-2 displays inhibitory effcts on CDK1/CycB, CDK2/CycA and CDK16/CycY kinases with IC50 values of 0.584 ?M, 0.706 ?M, and 0.605 ?M, respectively. NVP-2 induces cell apoptosis. NVP-2 Chemical Structure
  53. GC16959 NVP-LCQ195 NVP-LCQ195 Chemical Structure
  54. GC33353 ON-013100 ON-013100, an antineoplastic drug, acts a mitotic inhibitor that could inhibit Cyclin D1 expression. ON-013100 Chemical Structure
  55. GC15607 ON123300 multi-targeted kinase inhibitor,inhibits CDK4, Ark5, PDGFRβ, FGFR1, RET, and Fyn ON123300 Chemical Structure
  56. GC16511 OTS964 OTS964 is an orally active, high affinity and selective TOPK (T-lymphokine-activated killer cell-originated protein kinase) inhibitor with an IC50 of 28 nM. OTS964 is also a potent inhibitor of the cyclin-dependent kinase CDK11, which binds to CDK11B with a Kd of 40 nM. OTS964 Chemical Structure
  57. GC12011 P276-00 P276-00 (P276-00) is a potent cyclin-dependent kinase (CDK) inhibitor, which inhibits CDK9-cyclinT1, CDK4-cyclin D1, and CDK1-cyclinB with IC50s of 20 nM, 63 nM, and 79 nM, respectively.P276-00 (P276-00) shows antitumor activity on cisplatin-resistant cells. P276-00 Chemical Structure
  58. GC15421 Palbociclib (PD0332991) Isethionate Palbociclib (PD 0332991) isethionate is an orally active selective CDK4 and CDK6 inhibitor with IC50 values of 11 and 16 nM, respectively. Palbociclib (PD0332991) Isethionate has potent anti-proliferative activity and induces cell cycle arrest in cancer cells, which can be used in the research of HR-positive and HER2-negative breast cancer and hepatocellular carcinoma. Palbociclib (PD0332991) Isethionate Chemical Structure
  59. GC17935 PD 0332991 (Palbociclib) HCl Palbociclib (PD 0332991) monohydrochloride is an orally active selective CDK4 and CDK6 inhibitor with IC50 values of 11 and 16 nM, respectively. PD 0332991 (Palbociclib) HCl has potent anti-proliferative activity and induces cell cycle arrest in cancer cells, which can be used in the research of HR-positive and HER2-negative breast cancer and hepatocellular carcinoma. PD 0332991 (Palbociclib) HCl Chemical Structure
  60. GC40092 PD 0332991-d8 Palbociclib D8 (PD 0332991 D8) is a deuterium labeled Palbociclib. Palbociclib is a selective and orally active CDK4 and CDK6 inhibitor with IC50s of 11 and 16 nM, respectively. Palbociclib has the potential for ER-positive and HER2-negative breast cancer research. PD 0332991-d8 Chemical Structure
  61. GC32832 PF-06873600 PF-06873600 Chemical Structure
  62. GC62660 PF-07104091 PF-07104091 is a CDK2/cyclin E1 inhibitor, a selective ATP-site inhibitor targeting the cyclin-bound activated state of the kinase [1]. PF-07104091 Chemical Structure
  63. GC62661 PF-07104091 hydrate

    PF-07104091 hydrate is a potent and selective CDK2/cyclin E1 and GSK3β inhibitor, with Kis of 1.16 and 537.81 nM, respectively.

     PF-07104091 hydrate Chemical Structure
  64. GC11324 PHA-767491 A potent Cdc7 kinase inhibitor PHA-767491 Chemical Structure
  65. GC36892 PHA-767491 hydrochloride A potent Cdc7 kinase inhibitor PHA-767491 hydrochloride Chemical Structure
  66. GC15588 PHA-848125 PHA-848125 (PHA-848125) is a potent, ATP-competitive and dual inhibitor of CDK and Tropomyosin receptor kinase (TRK), with IC50s of 45, 150, 160, 363, 398 nM and 53 nM for cyclin A/CDK2, cyclin H/CDK7, cyclin D1/CDK4, cyclin E/CDK2, cyclin B/CDK1 and TRKA, respectively. PHA-848125 Chemical Structure
  67. GC39421 PNU112455A hydrochloride A Cdk2 and Cdk5 inhibitor PNU112455A hydrochloride Chemical Structure
  68. GC69747 PROTAC CDK12/13 Degrader-1

    PROTAC CDK12/13 Degrader-1 (7f) is a highly efficient and selective dual degrader of cell cycle-dependent kinases CDK12/CDK13, with DC50 values of 2.2 nM and 2.1 nM, respectively. PROTAC CDK12/13 Degrader-1 has anti-proliferative activity and can be used for breast cancer research.

     PROTAC CDK12/13 Degrader-1 Chemical Structure
  69. GC62666 PROTAC CDK2/9 Degrader-1 PROTAC CDK2/9 Degrader-1 (Compound F3) is a potent dual degrader for CDK2 (DC50=62 nM) and CDK9 (DC50=33 nM). PROTAC CDK2/9 Degrader-1 suppresses prostate cancer PC-3 cell proliferation (IC50=0.12 ?M) by effectively blocking the cell cycle in S and G2/M phases. PROTAC CDK2/9 Degrader-1 is a PROTAC by tethering CDK inhibitor with Cereblon ligand. PROTAC CDK2/9 Degrader-1 Chemical Structure
  70. GC32845 PROTAC CDK9 Degrader-1 PROTAC CDK9 Degrader-1 is a PROTAC connected by ligands for Cereblon and CDK as a selective CDK9 degrader. PROTAC CDK9 Degrader-1 Chemical Structure
  71. GC14707 Purvalanol A potent, and cell-permeable CDK inhibitor Purvalanol A Chemical Structure
  72. GC16268 Purvalanol B CDK1/CDK2/CDK4 inhibitor Purvalanol B Chemical Structure
  73. GC17400 R547 CDK1/2/4 inhibitor,ATP-competitive R547 Chemical Structure
  74. GC37522 RGB-286638 A multi-kinase inhibitor RGB-286638 Chemical Structure
  75. GC37523 RGB-286638 free base A multi-kinase inhibitor RGB-286638 free base Chemical Structure
  76. GC60324 Ribociclib D6 Ribociclib D6 (LEE011 D6) is a deuterium labeled Ribociclib. Ribociclib is a highly specific CDK4/6 inhibitor with IC50 values of 10 nM and 39 nM, respectively, and is over 1,000-fold less potent against the cyclin B/CDK1 complex. Ribociclib D6 Chemical Structure
  77. GC62638 Ribociclib D6 hydrochloride Ribociclib D6 hydrochloride Chemical Structure
  78. GC37529 Ribociclib succinate hydrate Ribociclib succinate hydrate (LEE011 succinate hydrate) is a highly specific CDK4/6 inhibitor with IC50 values of 10 nM and 39 nM, respectively, and is over 1,000-fold less potent against the cyclin B/CDK1 complex. Ribociclib succinate hydrate Chemical Structure
  79. GC12348 Ro 3306 An ATP-competitive, potent CDK1 inhibitor Ro 3306 Chemical Structure
  80. GC33360 Roniciclib (BAY 1000394) Roniciclib (BAY 1000394) is an orally bioavailable pan-cyclin dependent kinase (CDK) inhibitor, with IC50s of 5-25 nM for CDK1, CDK2, CDK3, CDK4, CDK7 and CDK9. Roniciclib (BAY 1000394) Chemical Structure
  81. GC11401 Roscovitine (Seliciclib,CYC202) Roscovitine (Seliciclib,CYC202) (Roscovitine) is an orally bioavailable and selective CDKs inhibitor with IC50s of 0.2 μM, 0.65 μM, and 0.7 μM for CDK5, Cdc2, and CDK2, respectively. Roscovitine (Seliciclib,CYC202) Chemical Structure
  82. GC32735 Samuraciclib hydrochloride (ICEC0942 hydrochloride) CT7001 hydrochloride (ICEC0942 hydrochloride) (CT7001 hydrochloride) is a potent, selective, ATP-competitive and orally active CDK7 inhibitor, with an IC50 of 41 nM. CT7001 hydrochloride (ICEC0942 hydrochloride) displays 45-, 15-, 230- and 30-fold selectivity over CDK1, CDK2 (IC50 of 578 nM), CDK5 and CDK9, respectively. CT7001 hydrochloride (ICEC0942 hydrochloride) inhibits the growth of breast cancer cell lines with GI50 values between 0.2-0.3 μM. CT7001 hydrochloride (ICEC0942 hydrochloride) has anti-tumor effects. Samuraciclib hydrochloride (ICEC0942 hydrochloride) Chemical Structure
  83. GC63736 Samuraciclib hydrochloride hydrate Samuraciclib (CT7001) hydrochloride hydrate is a potent, selective, ATP-competitive and orally active CDK7 inhibitor, with an IC50 of 41 nM. Samuraciclib hydrochloride hydrate displays 45-, 15-, 230- and 30-fold selectivity over CDK1, CDK2 (IC50 of 578 nM), CDK5 and CDK9, respectively. Samuraciclib hydrochloride hydrate inhibits the growth of breast cancer cell lines with GI50 values between 0.2-0.3 ?M. Samuraciclib hydrochloride hydrate has anti-tumor effects. Samuraciclib hydrochloride hydrate Chemical Structure
  84. GC62319 Samuraciclib trihydrochloride Samuraciclib trihydrochloride Chemical Structure
  85. GC11022 SB 218078 checkpoint kinase 1 (Chk1) inhibitor SB 218078 Chemical Structure
  86. GC12064 SB1317 A multi-kinase inhibitor SB1317 Chemical Structure
  87. GC33137 SEL120-34A SEL120-34A is a potent, selective, orally available, ATP-competitive CDK8 inhibitor, with IC50s of 4.4 nM and 10.4 nM for CDK8/CycC and CDK19/CycC, respectively, with antitumor activity. SEL120-34A Chemical Structure
  88. GC32898 SEL120-34A HCl SEL120-34A HCl is a potent, selective, orally available, ATP-competitive CDK8 inhibitor, with IC50s of 4.4 nM and 10.4 nM for CDK8/CycC and CDK19/CycC, respectively, with antitumor activity. SEL120-34A HCl Chemical Structure
  89. GC34355 SEL120-34A monohydrochloride SEL120-34A monohydrochloride is an ATP-competitive and selective CDK8 inhibitor, inhibits kinase activities of CDK8/CycC and CDK19/CycC complexes with IC50s of 4.4 nM and 10.4 nM, respectively, with a Kd of 3 nM for CDK8. SEL120-34A monohydrochloride weakly inhibits CDK9 (calculated IC50=1070 nM), but shows no obvious activity against CDK1, 2, 4, 6, 5, 7. SEL120-34A monohydrochloride inhibits phosphorylation of STAT1 S727 and STAT5 S726. Has anti-tumor activity. SEL120-34A monohydrochloride Chemical Structure
  90. GC37627 Senexin A Senexin A is a CDK8 inhibitor with an IC50 of 280 nM. Senexin A Chemical Structure
  91. GC19326 Senexin B Senexin B is a potent, highly water-soluble and bioavailable CDK8/19 inhibitor, with Kds of 140 nM for CDK8 and 80 nM for CDK19. Senexin B Chemical Structure
  92. GC32930 Simurosertib (TAK-931) Simurosertib (TAK-931) (TAK-931) is an orally active, selective and ATP-competitive cell division cycle 7 (CDC7) kinase inhibitor, with an IC50 of <0.3 nM. Simurosertib (TAK-931) has anti-cancer activity. Simurosertib (TAK-931) Chemical Structure
  93. GC11396 SNS-032 (BMS-387032) SNS-032 (BMS-387032) (BMS-387032) is a potent and selective inhibitor ofCDK2, CDK7, and CDK9 withIC50sof 38 nM, 62 nM and 4 nM, respectively. SNS-032 (BMS-387032) has antitumor effect. SNS-032 (BMS-387032) Chemical Structure
  94. GC39175 SR-4835 SR-4835 is a potent, highly selective and ATP competitive dual inhibitor of CDK12/CDK13 (CDK12: IC50=99 nM, Kd=98 nM; CDK13: Kd=4.9 nM). SR-4835 acts in synergy with DNA-damaging chemotherapy and PARP inhibitors and provokes triple-negative breast cancer (TNBC) cell death. SR-4835 Chemical Structure
  95. GC63201 SRI-29329 SRI-29329 is a specific CLK inhibitor, with IC50 values of 78 nM, 16 nM and 86 nM for CLK1, CLK2 and CLK4, respectively. SRI-29329 Chemical Structure
  96. GC15571 SU 9516 A pro-apoptotic Cdk2/cyclin A inhibitor SU 9516 Chemical Structure
  97. GC37709 SY-1365 SY-1365 (SY-1365) is a potent and first-in-class selective CDK7 inhibitor, with a Ki of 17.4 nM. SY-1365 exhibits anti-proliferative and apoptotic effects in solid tumor cell lines. SY-1365 possesses anti-tumor activity in hematological and multiple aggressive solid tumors. SY-1365 Chemical Structure
  98. GC65395 T025

    T025 is an orally active and highly potent inhibitor of Cdc2-like kinase (CLKs), with Kd values of 4.8, 0.096, 6.5, 0.61, 0.074, 1.5 and 32 nM for CLK1, CLK2, CLK3, CLK4, DYRK1A, DYRK1B and DYRK2, respectively. 

     T025 Chemical Structure
  99. GC69987 Tanuxiciclib

    Tanuxiciclib is a cell cycle cyclin-dependent kinase (CDK) inhibitor.

     Tanuxiciclib Chemical Structure
  100. GC69988 Tanuxiciclib trihydrochloride

    Tanuxiciclib trihydrochloride is a cell cycle cyclin-dependent kinase (CDK) inhibitor.

     Tanuxiciclib trihydrochloride Chemical Structure
  101. GC39162 TCMDC-135051 TCMDC-135051 is a highly selective and potent protein kinase PfCLK3 inhibitor with low off-target toxicity. TCMDC-135051 Chemical Structure

Items 101 to 200 of 222 total

per page
  2. 1
  3. 2
  4. 3

Set Descending Direction